Progyny (PGNY) Projected to Post Quarterly Earnings on Tuesday

Progyny (NASDAQ:PGNY) is expected to be announcing its earnings results after the market closes on Tuesday, February 25th. Analysts expect the company to announce earnings of $0.36 per share and revenue of $277.31 million for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Progyny Stock Performance

Shares of NASDAQ PGNY opened at $23.20 on Monday. The stock has a fifty day moving average of $19.84 and a 200-day moving average of $18.60. Progyny has a fifty-two week low of $13.39 and a fifty-two week high of $40.89. The stock has a market cap of $1.98 billion, a PE ratio of 40.00, a price-to-earnings-growth ratio of 2.39 and a beta of 1.34.

Insider Transactions at Progyny

In other news, Chairman David J. Schlanger bought 150,000 shares of the company’s stock in a transaction on Thursday, December 26th. The shares were acquired at an average cost of $14.68 per share, with a total value of $2,202,000.00. Following the completion of the transaction, the chairman now owns 228,269 shares of the company’s stock, valued at approximately $3,350,988.92. This trade represents a 191.65 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Peter Anevski purchased 209,500 shares of the business’s stock in a transaction on Monday, December 23rd. The shares were purchased at an average price of $14.48 per share, with a total value of $3,033,560.00. Following the completion of the purchase, the chief executive officer now owns 441,463 shares in the company, valued at approximately $6,392,384.24. This trade represents a 90.32 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 12.30% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on PGNY shares. JPMorgan Chase & Co. upped their target price on Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 28th. Canaccord Genuity Group cut their price objective on shares of Progyny from $18.00 to $17.00 and set a “hold” rating for the company in a research note on Wednesday, November 13th. Barclays reduced their target price on shares of Progyny from $30.00 to $17.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. Bank of America boosted their price target on shares of Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, February 11th. Finally, Truist Financial reiterated a “hold” rating and issued a $19.00 price objective (down previously from $26.00) on shares of Progyny in a report on Wednesday, November 13th. Nine research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $25.83.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.